Schutter Richard U. De Acquires 10,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 15th. The stock was bought at an average cost of $10.80 per share, for a total transaction of $108,000.00. Following the completion of the purchase, the director now directly owns 25,190 shares of the company’s stock, valued at $272,052. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at 11.03 on Monday. The company’s market cap is $3.84 billion. Valeant Pharmaceuticals Intl Inc has a 12-month low of $10.50 and a 12-month high of $38.50. The company has a 50-day moving average of $13.98 and a 200 day moving average of $18.38.

Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.06. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.34 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The company’s revenue for the quarter was down 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.55 EPS. On average, equities research analysts expect that Valeant Pharmaceuticals Intl Inc will post $3.89 EPS for the current year.

Insider Buying and Selling by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Your IP Address:

A number of equities research analysts recently weighed in on VRX shares. BMO Capital Markets raised their target price on shares of Valeant Pharmaceuticals Intl to $21.00 in a research note on Wednesday, March 1st. Royal Bank of Canada lowered their target price on shares of Valeant Pharmaceuticals Intl to $21.00 in a research note on Wednesday, March 1st. Guggenheim reaffirmed a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, February 7th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, February 9th. Finally, Jefferies Group LLC lowered their target price on shares of Valeant Pharmaceuticals Intl from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 1st. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $27.35.

Several hedge funds have recently modified their holdings of VRX. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Valeant Pharmaceuticals Intl by 357.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 14,471 shares of the specialty pharmaceutical company’s stock valued at $291,000 after buying an additional 11,308 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Valeant Pharmaceuticals Intl by 106.6% in the third quarter. BNP Paribas Arbitrage SA now owns 897,460 shares of the specialty pharmaceutical company’s stock valued at $22,033,000 after buying an additional 463,137 shares during the period. Academy Capital Management Inc. TX boosted its stake in shares of Valeant Pharmaceuticals Intl by 13.4% in the third quarter. Academy Capital Management Inc. TX now owns 649,959 shares of the specialty pharmaceutical company’s stock valued at $15,956,000 after buying an additional 76,638 shares during the period. Addison Capital Co purchased a new stake in shares of Valeant Pharmaceuticals Intl during the third quarter valued at about $224,000. Finally, Carl Domino Inc purchased a new stake in shares of Valeant Pharmaceuticals Intl during the third quarter valued at about $225,000. 64.34% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/schutter-richard-u-de-acquires-10000-shares-of-valeant-pharmaceuticals-intl-inc-vrx-stock/1708927.html

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *